Inhibikase Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IKT research report →
Companywww.inhibikase.com
Inhibikase Therapeutics, Inc. , a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.
- CEO
- Mark T. Iwicki
- IPO
- 2020
- Employees
- 15
- HQ
- Atlanta, GA, US
Price Chart
Valuation
- Market Cap
- $119.28M
- P/E
- -0.06
- P/S
- 0.00
- P/B
- 0.02
- EV/EBITDA
- -1.25
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.31%
- ROIC
- -33.17%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-48,259,189 · -75.36%
- EPS
- $-0.49 · 57.76%
- Op Income
- $-51,974,283
- FCF YoY
- -45.11%
Performance & Tape
- 52W High
- $2.26
- 52W Low
- $1.33
- 50D MA
- $1.82
- 200D MA
- $1.70
- Beta
- 0.96
- Avg Volume
- 2.01M
Get TickerSpark's AI analysis on IKT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 21, 26 | Aurentz Vincent | sell | 255,299 |
| Feb 21, 26 | Cabell Christopher | sell | 338,282 |
| Feb 21, 26 | Munshi Amit | sell | 19,089 |
| Jan 5, 26 | Iwicki Mark T | other | 4,982,706 |
| Jan 5, 26 | Cabell Christopher | other | 900,117 |
| Jan 5, 26 | McIntyre David | other | 986,319 |
| Nov 21, 25 | Sands Capital Life Sciences Pulse Fund II, L.P. | buy | 2,068,965 |
| Feb 21, 25 | Cabell Christopher | other | 0 |
| Feb 21, 25 | Aurentz Vincent | other | 0 |
| Feb 21, 25 | Munshi Amit | other | 57,265 |
Our IKT Coverage
We haven't published any research on IKT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IKT Report →